Merck secures Japanese approval for subcutaneous Keytruda (MRK:NYSE)
· seekingalpha.com
Merck wins Japan approval for subcutaneous KEYTRUDA QLEX/KEYJECT across Keytruda uses; 1–2 min dosing backed by Phase 3 data.
Merck (MRK) has secured Japanese regulatory approval for KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous injection, covering all ...